Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Best Pract Res Clin Obstet Gynaecol. 2008 Apr;22(2):407-21. Epub 2007 Sep 19.

Hormonal therapies and gynaecological cancers.

Author information

  • 1Mercy Hospital for Women, Heidelberg, Victoria 3084, Australia. AGarrett@mercy.com.au

Abstract

Hormonal therapy has an established place in the management of women with gynaecological malignancies, including first-line therapy for recurrent receptor-positive endometrial cancer and low-grade stromal sarcoma. There is no place for adjuvant hormonal treatment of these cancers after primary surgery. Primary treatment with either oral or intra-uterine progestagens to preserve fertility in younger women with endometrial carcinoma is effective in about 70% of cases. Response rates to tamoxifen in advanced/recurrent ovarian cancers approximates 10%. To the authors' knowledge, no studies that reasonably compare different progestagens, different routes of therapy, different doses and different hormonal preparations have been published.

PMID:
17884734
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk